Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Rheumatoid Arthritis
Interventions: pioglitazone, Sublingual nitroglycerine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 100 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Preeclampsia
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas

Conditions: Heart Transplantation
Interventions: Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions: Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 216
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 175 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: ranibizumab 0.5 or 2.0 mg/0.05 cc; Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Obesity, Type 2 Diabetes
Interventions: Almond Diet; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autistic Disorder, Autism
Interventions: Placebo, Risperidone high dose, Risperidone low dose; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more

Conditions: Posttraumatic Stress Disorder, Depression
Interventions: Placebo, Sertraline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 20 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypoxia, Hypercapnia
Interventions: L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Advanced Solid Tumors
Interventions: ASP1002, Bevacizumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Trifluridine-Tipiracil, Pembrolizumab, Pemetrexed, Carboplatin, Ramucirumab, Docetaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
Interventions: BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Achondroplasia
Interventions: BMN 333, Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Oakland, California • Wilmington, Delaware • Chicago, Illinois + 6 more

Conditions: Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions: Dapagliflozin 10 MG [Farxiga]; Drug
Lead sponsor: Emerald Clinical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Nicotine Dependence
Interventions: Nicotine; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Depression, Anhedonia
Interventions: Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution; Device · Behavioral · Drug
Lead sponsor: Erika Forbes; Other
Eligibility: 15 Years to 25 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Functional Constipation (FC)
Interventions: plecanatide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 25 more

Conditions: Hematopoietic Neoplasm
Interventions: SAR302503; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: San Francisco, California • Ann Arbor, Michigan • Rochester, Minnesota + 1 more

Conditions: Prostate Cancer
Interventions: Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Noonan Syndrome
Interventions: Vosoritide Injection; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 18 more

Search by objective public record fields.

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Pravastatin for Prevention of Preeclampsia

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

KRDI in Transplant-Eligible MM

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

Neural Mechanism of Aldosterone-induced Insulin Resistance

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

A Study of Sertraline to Prevent PTSD

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

HSCT for High Risk Inherited Inborn Errors

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Dapagliflozin Treatment in Type 2 Diabetes

Smoked Nicotine Induced Changes in Hormone Function, Mood States and Behaviors

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment